New response evaluation criteria in solid tumours : Revised RECIST guideline (version 1.1)EISENHAUER, E. A; THERASSE, P; RUBINSTEIN, L et al.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 228-247, issn 0959-8049, 20 p.Article

Thalidomide in solid tumours: the resurrection of an old drugSLEIJFER, Stefan; KRUIT, Wim H. J; STOTER, Gerrit et al.European journal of cancer (1990). 2004, Vol 40, Num 16, pp 2377-2382, issn 0959-8049, 6 p.Article

Metronomic chemotherapy for cancer treatment: a decade of clinical studiesROMITI, Adriana; COX, M. Christina; SARCINA, Ida et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 1, pp 13-33, issn 0344-5704, 21 p.Article

Evaluation of lymph nodes with RECIST 1.1SCHWARTZ, L. H; BOGAERTS, J; FORD, R et al.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 261-267, issn 0959-8049, 7 p.Article

Recommendations for the assessment of progression in randomised cancer treatment trialsDANCEY, J. E; DODD, L. E; FORD, R et al.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 281-289, issn 0959-8049, 9 p.Article

Evaluation of the response to treatment of solid tumours: a consensus statement of the International Cancer Imaging SocietyHUSBAND, J. E; SCHWARTZ, L. H; SPENCER, J et al.British journal of cancer. 2004, Vol 90, Num 12, pp 2256-2260, issn 0007-0920, 5 p.Article

Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: Results from the expansion cohort of a phase I studyKHAYAT, David; TEJPAR, Sabine; SPANO, Jean-Philippe et al.European journal of cancer (1990). 2013, Vol 49, Num 4, pp 790-797, issn 0959-8049, 8 p.Article

The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinomaJOHANNSEN, Manfred; SPITALERI, Gianluca; MILLER, Kurt et al.European journal of cancer (1990). 2010, Vol 46, Num 16, pp 2926-2935, issn 0959-8049, 10 p.Article

Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumoursCRESTA, S; SESSA, C; MACCIONI, E et al.European journal of cancer (1990). 2008, Vol 44, Num 13, pp 1829-1834, issn 0959-8049, 6 p.Article

Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG/EORTC studyRAVAUD, Alain; CERNY, Thomas; TERRET, Catherine et al.European journal of cancer (1990). 2005, Vol 41, Num 5, pp 702-707, issn 0959-8049, 6 p.Article

Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumoursINFANTE, Jeffrey R; WEISS, Glen J; RAMANATHAN, Ramesh K et al.European journal of cancer (1990). 2014, Vol 50, Num 17, pp 2897-2904, issn 0959-8049, 8 p.Article

Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseasesGUILHAUMOU, Romain; SIMON, Nicolas; QUARANTA, Sylvie et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 5, pp 1191-1198, issn 0344-5704, 8 p.Article

Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumoursROGALSKA, Aneta; SZWED, Marzena; JOZWIAK, Zofia et al.Mutation research. Genetic toxicology and environmental mutagenesis (Print). 2010, Vol 700, Num 1-2, pp 1-10, issn 1383-5718, 10 p.Article

Epoetin beta (neorecormon®) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy : a meta-analysisBOOGAERTS, M; OBERHOFF, C; TEN BOKKEL HUININK, W et al.Anticancer research. 2006, Vol 26, Num 1B, pp 479-484, issn 0250-7005, 6 p.Article

Disease-free survival as an end-point in the treatment of solid tumours - Perspectives from clinical trials and clinical practiceROBINSON, Andrew G; BOOTH, Christopher M; EISENHAUER, Elizabeth A et al.European journal of cancer (1990). 2014, Vol 50, Num 13, pp 2298-2302, issn 0959-8049, 5 p.Article

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignanciesGERECITANO, John F; STEPHENSON, Joe J; LEWIS, Nancy L et al.Investigational new drugs. 2013, Vol 31, Num 2, pp 355-362, issn 0167-6997, 8 p.Article

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumoursGREGORC, Vanesa; CITTERIO, Giovanni; DEL MASCHIO, Alessandro et al.European journal of cancer (1990). 2010, Vol 46, Num 1, pp 198-206, issn 0959-8049, 9 p.Article

Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumoursWUMKES, M. L; VAN DER VELDEN, A. M. T; RIJKERS, G. T et al.Vaccine. 2013, Vol 31, Num 52, pp 6177-6184, issn 0264-410X, 8 p.Article

Recommendations for capture, validation and summarisation of data from studies using RECISTPAULES, Melanie; CASEY, Michelle; WILLIAMS, Grant et al.European journal of cancer (1990). 2011, Vol 47, Num 5, pp 697-701, issn 0959-8049, 5 p.Article

Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy : results of the neoprevent studyDE CASTRO, Javier; ORDONEZ, Amalio; ISIA, Dolores et al.Cancer chemotherapy and pharmacology. 2007, Vol 59, Num 1, pp 35-42, issn 0344-5704, 8 p.Article

A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) studyGEOERGER, Birgit; ESTLIN, Edward J; PRADOS, Raquel et al.European journal of cancer (1990). 2012, Vol 48, Num 3, pp 289-296, issn 0959-8049, 8 p.Article

Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working groupSTONE, A. M; BUSHNELL, W; DENNE, J et al.European journal of cancer (1990). 2011, Vol 47, Num 12, pp 1763-1771, issn 0959-8049, 9 p.Article

The potential of statins as part of anti-cancer treatmentSLEIJFER, Stefan; VAN DER GAAST, Ate; PLANTING, André S. Th et al.European journal of cancer (1990). 2005, Vol 41, Num 4, pp 516-522, issn 0959-8049, 7 p.Article

Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumoursDELORD, J. P; TOURANI, J. M; LEFRESNE, F et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 3, pp 647-656, issn 0344-5704, 10 p.Article

Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumoursDE JONGE, M. J. A; DUMEZ, H; KITZEN, J. J. E. M et al.European journal of cancer (1990). 2011, Vol 47, Num 9, pp 1328-1335, issn 0959-8049, 8 p.Article